QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)

Kymera Therapeutics (KYMR) Stock Forecast, Price & News

$14.75
-0.58 (-3.78%)
(As of 09/27/2023 ET)
Compare
Today's Range
$14.70
$15.72
50-Day Range
$15.25
$23.88
52-Week Range
$14.70
$39.85
Volume
390,801 shs
Average Volume
479,241 shs
Market Capitalization
$817.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.10

Kymera Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
226.1% Upside
$48.10 Price Target
Short Interest
Bearish
13.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.55) to ($3.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

782nd out of 976 stocks

Biological Products, Except Diagnostic Industry

125th out of 159 stocks


KYMR stock logo

About Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

KYMR Price History

KYMR Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The Latest Analyst Ratings for Kymera Therapeutics
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Kymera Therapeutics: A Status Update
Expert Ratings for Kymera Therapeutics
Kymera Therapeutics (NASDAQ: KYMR)
What 5 Analyst Ratings Have To Say About Kymera Therapeutics
Kymera Therapeutics (KYMR) Gets a Buy from Stifel Nicolaus
See More Headlines
Receive KYMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KYMR Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KYMR
Fax
N/A
Employees
181
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.10
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+226.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-154,810,000.00
Net Margins
-305.01%
Pretax Margin
-305.01%

Debt

Sales & Book Value

Annual Sales
$46.83 million
Book Value
$8.93 per share

Miscellaneous

Free Float
46,175,000
Market Cap
$817.30 million
Optionable
Not Optionable
Beta
1.51
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Bruce L. Booth D.Phil. (Age 49)
    DPHIL, Ph.D., Co-Founder & Chairman
    Comp: $79.19k
  • Dr. Nello Mainolfi M.D. (Age 45)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $975.2k
  • Mr. Bruce N. Jacobs CFAMr. Bruce N. Jacobs CFA
    Chief Financial Officer
  • Dr. Jared A. Gollob M.D. (Age 58)
    Chief Medical Officer
    Comp: $637.81k
  • Dr. Jeremy G. Chadwick Ph.D. (Age 60)
    Chief Operating Officer
  • Mr. Michael J. Todisco (Age 58)
    VP of Accounting & Fin.
  • Mr. Vijay Sabesan (Age 51)
    Sr. VP of Technical Operations
  • Ms. Justine E. Koenigsberg
    VP of Investor Relations
  • Ms. Ellen V. Chiniara Esq. (Age 64)
    J.D., Chief Legal Officer & Corp. Sec.
  • Ms. Melissa Brody
    VP of Bus. Devel.













KYMR Stock - Frequently Asked Questions

Should I buy or sell Kymera Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KYMR shares.
View KYMR analyst ratings
or view top-rated stocks.

What is Kymera Therapeutics' stock price forecast for 2023?

9 Wall Street research analysts have issued 1-year target prices for Kymera Therapeutics' stock. Their KYMR share price forecasts range from $31.00 to $85.00. On average, they predict the company's stock price to reach $48.10 in the next twelve months. This suggests a possible upside of 226.1% from the stock's current price.
View analysts price targets for KYMR
or view top-rated stocks among Wall Street analysts.

How have KYMR shares performed in 2023?

Kymera Therapeutics' stock was trading at $24.96 on January 1st, 2023. Since then, KYMR shares have decreased by 40.9% and is now trading at $14.75.
View the best growth stocks for 2023 here
.

When is Kymera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our KYMR earnings forecast
.

How were Kymera Therapeutics' earnings last quarter?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.03. The business had revenue of $16.51 million for the quarter, compared to analysts' expectations of $13.93 million. Kymera Therapeutics had a negative net margin of 305.01% and a negative trailing twelve-month return on equity of 33.17%. Kymera Therapeutics's revenue was up 43.4% on a year-over-year basis. During the same period last year, the firm earned ($0.78) earnings per share.

What ETFs hold Kymera Therapeutics' stock?

ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Simplify Propel Opportunities ETF (SURI).

What other stocks do shareholders of Kymera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).

When did Kymera Therapeutics IPO?

(KYMR) raised $126 million in an initial public offering (IPO) on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO.

What is Kymera Therapeutics' stock symbol?

Kymera Therapeutics trades on the NASDAQ under the ticker symbol "KYMR."

Who are Kymera Therapeutics' major shareholders?

Kymera Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.82%), State Street Corp (4.73%), Rock Springs Capital Management LP (2.68%), Wasatch Advisors LP (2.16%), Dimensional Fund Advisors LP (1.52%) and Geode Capital Management LLC (1.45%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas.
View institutional ownership trends
.

How do I buy shares of Kymera Therapeutics?

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kymera Therapeutics' stock price today?

One share of KYMR stock can currently be purchased for approximately $14.75.

How much money does Kymera Therapeutics make?

Kymera Therapeutics (NASDAQ:KYMR) has a market capitalization of $817.30 million and generates $46.83 million in revenue each year. The company earns $-154,810,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis.

How many employees does Kymera Therapeutics have?

The company employs 181 workers across the globe.

How can I contact Kymera Therapeutics?

Kymera Therapeutics' mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The official website for the company is www.kymeratx.com. The company can be reached via phone at 857-285-5300 or via email at ir@kymeratx.com.

This page (NASDAQ:KYMR) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -